Sandbox fungal meningitis: Difference between revisions
Jump to navigation
Jump to search
Line 108: | Line 108: | ||
<div class="mw-collapsible mw-collapsed"> | <div class="mw-collapsible mw-collapsed"> | ||
===Cryptococcus | ===Cryptococcus HIV/AIDS===<ref name="pmid24052889">Antinori S (2013) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=24052889 New Insights into HIV/AIDS-Associated Cryptococcosis.] ''ISRN AIDS'' 2013 ():471363.http://dx.doi.org/10.1155/2013/471363 DOI:10.1155/2013/471363] PMID: [http://pubmed.gov/24052889 24052889]</ref> | ||
<div class="mw-collapsible-content"> | <div class="mw-collapsible-content"> | ||
Line 120: | Line 120: | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Induction Phrase(for 2 wks)'' | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Induction Phrase(for 2 wks)'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amphotericin B deoxycholate]] 0.7 mg/kg/day''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amphotericin B deoxycholate]] 0.7 mg/kg/day IV''''' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[5-Fluorocytosine]] 100 mg/kg/day''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[5-Fluorocytosine]] 100 mg/kg/day PO''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Consolidation phase(for 8 wks)'' | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Consolidation phase(for 8 wks)'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluconazole]] 400 mg/day'''''<BR>''OR''<BR>▸ '''''[[Itraconazole]] 400 mg/day''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluconazole]] 400 mg/day PO'''''<BR>''OR''<BR>▸ '''''[[Itraconazole]] 400 mg/day''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Maintenance phase'' | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Maintenance phase'' | ||
Line 139: | Line 139: | ||
</div></div> | </div></div> | ||
<div class="mw-collapsible mw-collapsed"> | |||
===Cryptococcus Immunocompetent===<ref name="pmid22763808">Jackson A, van der Horst C (2012) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=22763808 New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis.] ''Curr HIV/AIDS Rep'' 9 (3):267-77. [http://dx.doi.org/10.1007/s11904-012-0127-7 DOI:10.1007/s11904-012-0127-7] PMID: [http://pubmed.gov/22763808 22763808]</ref> | |||
<div class="mw-collapsible-content"> | |||
{| | |||
|- | |||
| valign=top | | |||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0"; | |||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Cryptococcus, Immunocompetent]]}}'' | |||
|- | |||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Induction Phrase(for 2 wks)'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Amphotericin B]] 0.7-1 mg/kg/day IV'''''<BR>''OR''<BR>▸ '''''[[Liposomal amphotericin B]] 5 mg/kg/day PO | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[5-Fluorocytosine]] 25 mg/kg PO q6h''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Consolidation phase(for 8 wks)'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluconazole]] 400 mg/day PO''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Maintenance phase(for 12 mo)'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluconazole]] 200 mg/day''''' | |||
|- | |||
|} | |||
|} | |||
</div></div> | |||
==References== | |||
{{reflist|2}} | |||
[[Category:Needs overview]] | |||
[[Category:Primary care]] | |||
[[Category:Disease]] | |||
[[Category:Infectious disease]] | |||
[[Category:Neurology]] | |||
[[Category:Emergency medicine]] | |||
[[Category:Diseases involving the fasciae]] | |||
[[Category:Inflammations]] | |||
[[Category:Neurological disorders]] |
Revision as of 17:18, 20 January 2014
Meningitis Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Sheng Shi, M.D. [2]
fungal meningitis
Blastomyces
|
Candidiasis
|
Histoplasma
|
Coccidioides
|
===Cryptococcus HIV/AIDS===[1]
|
===Cryptococcus Immunocompetent===[2]
|
References
- ↑ Antinori S (2013) New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS 2013 ():471363.http://dx.doi.org/10.1155/2013/471363 DOI:10.1155/2013/471363] PMID: 24052889
- ↑ Jackson A, van der Horst C (2012) New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis. Curr HIV/AIDS Rep 9 (3):267-77. DOI:10.1007/s11904-012-0127-7 PMID: 22763808